{"entity":{"id":"nct07379047","kind":"trial","name":"Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","aka":["GISTAR-1"],"tldr":"A phase 2/3 trial testing NB003 in gastrointestinal stromal tumour, now recruiting.","summary":"Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumours (GIST) is a phase 2/3 interventional study registered as NCT07379047, led by Ningbo Newbay Technology Development, and recruiting on the registry. Official title: A Multicenter, Open-label Clinical Study to Evaluate the Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumours (GIST). Planned enrolment is 255 participants (estimated). The study started in 2026-05-11 and primary completion is expected in 2028-08-01. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07379047","url":"https://clinicaltrials.gov/study/NCT07379047"}],"tags":["ctgov-ingest"],"related":[],"cancers":["gist"],"sections":[],"technologies":[],"targets":[],"drugs":["nb003"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07379047","phase":"2/3","setting":"A Multicenter, Open-label Clinical Study to Evaluate the Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","sponsor":"Ningbo Newbay Technology Development","started":"2026-05-11","startedType":"actual","enrolled":255,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07379047/","neighbours":{"cancer":[{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/"}],"drug":[{"id":"nb003","kind":"drug","name":"NB003","route":"/drugs/nb003/"}]}}